25 |
ABL PROTO-ONCOGENE 1, NON-RECEPTOR TYROSINE KINASE |
ABL1 |
ABL |
CHDSKM |
JTK7 |
bcr/abl |
c-ABL |
c-ABL1 |
p150 |
v-abl |
189980 |
76 |
ENSG00000097007 |
OTTHUMG00000020813 |
P00519 |
ABL1_HUMAN |
Abelson tyrosine-protein kinase 1 |
Proto-oncogene c-Abl |
Abelson murine leukemia viral oncogene homolog 1 |
Tyrosine-protein kinase ABL1 |
PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (EC 2.7.1.112) (P150) (C- ABL). [SOURCE:UNIPROT/SWISSPROT;ACC:P00519] |
BE0000014 |
PA24413 |
4 |
1923 |
NP_005148 |
NM_005157 |
T63505 |
Human Readable Name | DRUGGABLE GENOME |
Target Class | Enzymes |
Target Subclass | EC:2.7.10.2 |
Uniprot Status | Swiss-Prot |
Interpro Short Name | Ser-Thr/Tyr_kinase_cat_dom |
Human Readable Name | KINASE |
Interpro Name | Serine-threonine/tyrosine-protein kinase catalytic domain |
Interpro Acc | IPR001245 |
Uniprot Evidence | 1: Evidence at protein level |
Interpro Type | Domain |
Target Subclass | 2.7.10.2 |
Target Main Class | Enzymes |
Initial Gene Query | ABL |
Counted Citations from 1950-2000 | 7889 |
GuideToPharmacology Gene Category Name | Abl family |
GuideToPharmacology Gene Category ID | 553 |
Gene Biotype | PROTEIN_CODING |
KINASE |
TYROSINE KINASE |
DRUG RESISTANCE |
DRUGGABLE GENOME |
CLINICALLY ACTIONABLE |
ENZYME |
allosteric modulator |
inhibitor (inhibitory) |
Mechanism of Interaction | Tyrosine-protein kinase ABL inhibitor |
Direct Interaction | yes |
Details of the Assay for Interaction | Two assays used: a radiometric filter-binding assay and microfluidic mobility shift technology (Caliper assay). |
inhibitor (inhibitory) |
Trial Name | nilotinib , AMN-107,Tasigna |
Novel drug target | Established target |
Variant Effect | gain-of-function |
inhibitor (inhibitory) |
Drug family | BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor |
Alteration | ABL1:T315I |
Alteration | ABL1__BCR |
inhibitor (inhibitory) |
Variant Effect | gain-of-function |
Pathway | activation |
Clinical Status | NCCN guidelines |
inhibitor (inhibitory) |
Mechanism of Interaction | Tyrosine-protein kinase ABL inhibitor |
Direct Interaction | yes |
Specific Action of the Ligand | Inhibition |
inhibitor (inhibitory) |
Details of the Assay for Interaction | Inhibition of native ABL kinase activity. |
Specific Action of the Ligand | Inhibition |
Endogenous Drug? | False |
inhibitor (inhibitory) |
Mechanism of Interaction | Tyrosine-protein kinase ABL inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Specific Action of the Ligand | Inhibition |
Endogenous Drug? | False |
Direct Interaction? | False |
inhibitor (inhibitory) |
Mechanism of Interaction | Tyrosine-protein kinase ABL inhibitor |
Direct Interaction | yes |
Specific Action of the Ligand | Inhibition |
inhibitor (inhibitory) |
Mechanism of Interaction | Tyrosine-protein kinase ABL inhibitor |
Direct Interaction | yes |
Specific Action of the Ligand | Inhibition |
multitarget |
inhibitor (inhibitory) |
combination therapy | [Nilotinib,Dasatinib] |
Drug family | [BCR-ABL inhibitor 2nd gen] |
Alteration | ABL1:T315I |
inhibitor (inhibitory) |
Fusion protein | BCR:ABL1 |
Trial Name | imatinib mesylate, STI 571,Gleevec, Glivec |
Novel drug target | Established target |
inhibitor (inhibitory) |
Mechanism of Interaction | Tyrosine-protein kinase ABL inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | Tyrosine-protein kinase ABL inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | Tyrosine-protein kinase ABL inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Trial Name | XL228 |
Novel drug target | Established target |
Mechanism of Interaction | Tyrosine-protein kinase ABL inhibitor |
inhibitor (inhibitory) |
Mechanism of Interaction | Tyrosine-protein kinase ABL inhibitor |
Direct Interaction | yes |
Specific Action of the Ligand | Inhibition |
inhibitor (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | Tyrosine-protein kinase ABL inhibitor |
inhibitor (inhibitory) |
Specific Action of the Ligand | Inhibition |
Endogenous Drug? | False |
Direct Interaction? | False |
inhibitor (inhibitory) |
Mechanism of Interaction | Tyrosine-protein kinase ABL inhibitor |
Direct Interaction | yes |
n/a |
Trial Name | masitinib, AB1010 |
Novel drug target | Established target |
inhibitor (inhibitory) |
Mechanism of Interaction | Tyrosine-protein kinase ABL inhibitor |
Direct Interaction | yes |
n/a |
combination therapy | Dasatinib;Venetoclax |
Drug family | BCR-ABL inhibitor 2nd gen;BCL2 inhibitor |
Alteration | ABL1__BCR |
n/a |
Drug family | Pan-kinase inhibitor |
Alteration | ABL1:V299L |
n/a |
Drug family | ALK inhibitor |
Alteration | ABL1:V299L |
n/a |
Trial Name | ENMD-2076 |
Novel drug target | Established target |
n/a |
combination therapy | Trametinib;Imatinib |
Drug family | MEK inhibitor;BCR-ABL inhibitor 1st gen&KIT inhibitor |
Alteration | PRKCH:amp;ABL1__BCR |
inhibitor (inhibitory) |
ABL1 | Ensembl Gene Name |
Gene Biotype | PROTEIN_CODING |
ABL1_HUMAN | Uniprot Id |
P00519 | Uniprot Accession |
ENSG00000097007 | Ensembl Gene Id |
Target Subclass | 2.7.10.2 |
Target Main Class | Enzymes |
25 | Entrez Gene ID |
Initial Gene Query | ABL |
Counted Citations from 1950-2000 | 7889 |
KINASE |
ENSG00000097007 | Ensembl Gene Id |
ABL1 | Display Id |
PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (EC 2.7.1.112) (P150) (C- ABL). [SOURCE:UNIPROT/SWISSPROT;ACC:P00519] | Description |
Human Readable Name | DRUGGABLE GENOME |
DRUGGABLE GENOME |
TYROSINE-PROTEIN KINASE ABL1 | Uniprot Protein Name |
ENSG00000097007 | Ensembl Gene Id |
25 | Entrez Gene Id |
Uniprot Status | Swiss-Prot |
Interpro Short Name | Ser-Thr/Tyr_kinase_cat_dom |
Human Readable Name | KINASE |
KINASE, DRUGGABLE GENOME |
ABL1 | Gene Symbol |
Target Class | Enzymes |
Target Subclass | EC:2.7.10.2 |
76 | HUGO Gene ID |
76 | HUGO Gene Symbol |
ABL proto-oncogene 1, non-receptor tyrosine kinase | HUGO Gene Name |
GuideToPharmacology Gene Category Name | Abl family |
GuideToPharmacology Gene Category ID | 553 |
ENZYME |
25 | CKB Entrez Id |
ABL1 | CKB Gene Synonym |
ABL | CKB Gene Synonym |
PA24413 | PharmGKB ID |
25 | Entrez Gene ID |
4 | CIViC Gene ID |
DRUG RESISTANCE, CLINICALLY ACTIONABLE |
ABL1 | DrugBank Gene Name |
P00519 | UniProt Accession |
25 | Entrez Gene Id |
ENSG00000097007 | Gene Symbol |
ABL1 | Ensembl Id |
DRUGGABLE GENOME |
25 | Entrez Gene Id |
ABL1 | MyCancerGenome Gene Symbol |
ABL | MyCancerGenome Reported Gene Name |
JTK7 | GENE_SYMBOL |
ABL1 | GENE_SYMBOL |
Tyrosine-protein kinase ABL1 | UNIPROT |
p150 | OncoKB Gene Synonym |
25 | OncoKB Entrez Id |
v-abl | OncoKB Gene Synonym |
Tyrosine-protein kinase ABL1 | Gene Name |
P00519 | UniProt ID |
KINASE |
ABL | GO Gene Synonym |
JTK7 | GO Gene Synonym |
KINASE, TYROSINE KINASE |
ABL1 | Gene Symbol |
CLINICALLY ACTIONABLE |
25 | Gene ID |
ABL | dGene Synonym |
JTK7 | dGene Synonym |
KINASE, TYROSINE KINASE |
ABL | TTD Gene Abbreviation |
T63505 | TTD Target ID |
CLINICALLY ACTIONABLE |
CLINICALLY ACTIONABLE |
CLINICALLY ACTIONABLE |
DRUG RESISTANCE |